Innovent Biopharmaceutical Technology (hangzhou) Co., Ltd.

This study tests a new drug called picankibart in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. The goal is to see if it can safely reduce skin plaques by at least 75% within 16 weeks. Participants will receive either the drug or a placebo, and their skin impr…

This early-phase study tests a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and understand side effects. About 493 adults with certain cancers like colorectal, lung, or pancre…

This study tests a new drug called picankibart for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 222 adults will get either the drug or a placebo as a shot under the skin. The goal is to see if the drug improves joint symptoms and …

This study tests a combination of two drugs, IBI310 and sintilimab, in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combo can shrink tumors or slow cancer growth better than current treatments. About 680 adults who have not had pr…

This phase 3 trial tests a new drug called IBI354, given with or without another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The study aims to see if the new combination helps de…